Press Releases News / Events Overview Press Releases In The News IR Calendar Email Alerts Year All Years 2021 2020 2019 Category All Releases Financial Releases NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth Jun 08, 2021 12:30pm EDT NeuBase Therapeutics Announces Speakers for Virtual R&D Day Taking Place on June 8th Jun 02, 2021 9:00am EDT NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer May 25, 2021 8:00am EDT NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer May 20, 2021 8:00am EDT NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021 May 14, 2021 12:30pm EDT NeuBase Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2021 May 13, 2021 4:05pm EDT NeuBase Therapeutics Appoints Gerald J. McDougall to Board of Directors May 12, 2021 9:00am EDT NeuBase Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference Apr 27, 2021 8:00am EDT NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Apr 26, 2021 4:01pm EDT NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock Apr 22, 2021 9:07am EDT 1 2 3 4 5 6 Next
NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth Jun 08, 2021 12:30pm EDT
NeuBase Therapeutics Announces Speakers for Virtual R&D Day Taking Place on June 8th Jun 02, 2021 9:00am EDT
NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer May 25, 2021 8:00am EDT
NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021 May 14, 2021 12:30pm EDT
NeuBase Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2021 May 13, 2021 4:05pm EDT
NeuBase Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference Apr 27, 2021 8:00am EDT
NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Apr 26, 2021 4:01pm EDT
NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock Apr 22, 2021 9:07am EDT
